Cancer Vaccines in the World of Immune Suppressive Monocytes (CD14+HLA-DRlo/neg Cells): The Gateway to Improved Responses by Rebecca R. Laborde et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW ARTICLE
published: 04 April 2014
doi: 10.3389/fimmu.2014.00147
Cancer vaccines in the world of immune suppressive
monocytes (CD14+HLA-DRlo/neg cells): the gateway to
improved responses
Rebecca R. Laborde1,Yi Lin2, Michael P. Gustafson1, Peggy A. Bulur 1 and Allan B. Dietz 1*
1 Human Cellular Therapy Laboratory, Division of Transfusion Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
2 Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
Edited by:
Lisa Helene Butterfield, University of
Pittsburgh, USA
Reviewed by:
Geanncarlo Lugo-Villarino, Centre
National de la Recherche Scientifique,
France
Matthew Collin, Newcastle
University, UK
*Correspondence:
Allan B. Dietz, Human Cellular
Therapy Laboratory, Department of
Laboratory Medicine and Pathology,
Division of Transfusion Medicine,
Mayo Clinic, 200 First Street
Southwest, Rochester, MN 55905,
USA
e-mail: dietz.allan@mayo.edu
Dendritic cells are an important target in cancer immunotherapy based on their critical
role in antigen presentation and response to tumor development.The capacity of dendritic
cells to stimulate anti-tumor immunity has led investigators to use these cells to mediate
anti-tumor responses in a number of clinical trials. However, these trials have had mixed
results. The typical method for generation of ex vivo dendritic cells starts with the purifi-
cation of CD14+ cells. Our studies identified a deficiency in the ability to generate mature
dendritic cell using CD14+ cells from cancer patients that corresponded with an increased
population of monocytes with altered surface marker expression (CD14+HLA-DRlo/neg).
Further studies identified systemic immune suppression and increased concentrations of
CD14+HLA-DRlo/neg monocytes capable of inhibitingT-cell proliferation and DC maturation.
Together, these findings strongly suggest that protocols aimed at immune stimulation via
monocytes/dendritic cells, if optimized on normal monocytes or in systems without these
suppressive monocytes, are unlikely to engender effective DC maturation in vitro or effi-
ciently trigger DC maturation in vivo. This highlights the importance of developing optimal
protocols for stimulating DCs in the context of significantly altered monocyte phenotypes
often seen in cancer patients.
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DENDRITIC CELLS AS CANCER VACCINES
Dendritic cells are potent signal transducers in the immune sys-
tem. These cells present antigen, are the essential bridge between
the innate and adaptive arms of the immune system, and serve
as regulators to modulate immune response to pathogenic inva-
sion, tissue injury, and tumor development. As such, dendritic
cells have received significant focus as a promising vehicle for the
development of vaccines for cancer immunotherapy. We now have
a more complete understanding of DC ontology with the realiza-
tion that DCs exist in diverse subsets, all capable of activating T
cells but possessing unique functions. DCs are classified into two
broad categories. The first are monocyte-derived DCs resulting
from stimulation due to inflammation or infection. The second
category are steady-state DCs which include resident CD8+ DCs
located in the thymus, resident CD8−DCs in the spleen, plasmacy-
toid DCs (pDCs), migratory DCs, and Langerhans cells [reviewed
in Ref. (1, 2)]. Each of these classes of DCs has been demonstrated
to play a key role in immune surveillance and response but for the
purpose of DC-based vaccines for immunotherapy in cancer, the
focus has been on CD14+ monocyte-derived DCs.
The in vivo pathways associated with the development of den-
dritic cells from monocyte precursors and the mechanisms and
consequences of pathogenic activation have been described (3,
4). Briefly, DCs arise from monocyte progenitors into an imma-
ture state (iDC) responsible for immune surveillance via pathogen
detection. Once activated, iDC further differentiate into mature
dendritic cells (mDC) and travel to lymph nodes to activate the
adaptive (typically T- and B-cell responses) and innate immune
response (5). DCs also play a role in limiting the immune response
against self antigen (self-tolerance) as well as limiting response to
tissue damage in the absence of pathogenic signals (6). iDC can
suppress immunity and have been shown to be capable of eliminat-
ing antigen-specific T cells (7). Restriction of the capacity of iDC
to differentiate into mDC has been a mechanism used by viruses,
parasites, and bacteria to maintain a state of self-tolerance and to
enable microbial pathology (8–10). Thus, manipulation and main-
tenance of a state of iDC with a block on the ability to differentiate
into mDC is a key mechanism of immune suppression.
To generate mDC in vitro for clinical use, the CD14+ mono-
cytes are the preferred precursor due to their abundance and
ease of collection. CD14+ monocytes are purified from mononu-
clear cells via adherence to plastic, antibody selection, or size
centrifugation and used as source material to differentiate DC.
To drive the immune response, the DCs are pulsed with tumor
antigens in the form of peptides, RNA, or lysates derived from
whole tumors or cell lines (11, 12). Additionally, viruses can be
a potent mechanism to deliver tumor antigens (13–15). Manu-
facturing methods reported among clinical trials vary greatly. As
a variety of methods with subtle optimizations of DC cultures
have been published, there are few constants (DC activation state,
tumor source, patient status, underlying disease etc.) that allow
useful comparisons between the growing numbers of trials and
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the underlying methods and characteristics used to generate and
describe the drug (in this case DC). Often, this key aspect of drug
development (optimizing and describing the purity and potency
of the drug) is overlooked. However, one constant regarding the
majority of the trials remains; that is the use of CD14+ cells as a
starting material.
MONOCYTE PRECURSORS OF DC ARE OFTEN ALTERED IN
CANCER PATIENTS AND ARE IMMUNE SUPPRESSIVE
In our efforts to establish a DC vaccine protocol, we worked
to optimize the maturation of DCs in cancer patients. During
those studies, we discovered that in many patients, CD14+-isolated
monocytes were incapable of differentiation into mDC using stan-
dard DC generation protocols (16–18). This result that monocytes
from cancer patients were potentially altered in their capacity to
differentiate into DC, led us to search for correlative markers. We
identified an increased population of monocytes with an altered
surface marker expression (CD14+HLA-DRlo/neg) in a number
of malignancies (16–20) (Figure 1A). This phenotype has also
been reported by others in melanoma (21–23), bladder cancer
(24), non-small cell lung cancer (25), and hepatocellular can-
cer (26, 27). Our studies in glioblastoma identified evidence of
systemic immune suppression and increased concentrations of
CD14+HLA-DRlo/neg monocytes capable of inhibiting T-cell pro-
liferation and DC maturation that could also be re-capitulated
in vitro co-culture systems using tumor cell lines (18). These
same immunosuppressive monocytes have been characterized
with increased populations in bladder carcinoma that significantly
correlate with decreased T-cell proliferation and IFN-γ produc-
tion (24). These cells suppress immune function in multiple ways
(Table 1), and therefore must be considered for any approach to
DC vaccine strategies.
There is also mounting evidence that correlates increased
concentrations of CD14+HLA-DRlo/neg monocytes in patients
with poor clinical outcome. Populations of CD14+HLA-DRlo/neg
monocytes and TGF-β levels were significantly expanded in
metastatic melanoma patients as compared to healthy donors and
correlated to a lack of response to administered granulocyte–
macrophage colony-stimulation factor (GM-CSF) vaccine (22).
Increased CD14+HLA-DRlo/neg monocytes correlated to both
extrathoracic metastasis and poor response to chemotherapy
in non-small lung cancer patients (25). Increased CD14+HLA-
DRlo/neg monocytes are associated with more aggressive disease
and poorer prognosis in lymphoma (16) and hepatocellular car-
cinoma (40). Increased CD14+HLA-DRlo/neg monocytes were
associated with decreased time to progression in patients with
chronic lymphocytic leukemia (CLL) (19). Increased CD14+HLA-
DRlo/neg monocytes and decreased CD4+ T cells can predict poor
overall survival across a number of malignancies (20).
The finding that CD14+HLA-DRlo/neg monocytes are
detectable systemically in patients with a variety of malignancies
and that they are functionally immune suppressive raises impor-
tant questions regarding their influence in ex vivo DC vaccine
preparations. To address this, we have studied the effects of these
altered monocytes on mDC generation across several cancer types
using an ex vivo culture system. Briefly, CD14+ mononuclear cells
were isolated from buffy coats or apheresis leukoreduction system
FIGURE 1 | Monocyte and dendritic cell defects in cancer. (A) Cancer
patients have an increased percentage of CD14+HLA-DRlo/neg monocytes in
circulation. Peripheral blood of healthy volunteers and cancer patients was
analyzed by flow cytometry for immune phenotype. (B) Monocytes from
cancer patients have decreased capacity to differentiate to mDC (CD83+)
under a variety of stimulation conditions. Monocytes were selected from
blood of healthy volunteers (HV) or cancer patients (GBM, glioblastoma
multiforme LYM, B-cell lymphoma; RCC, renal cell carcinoma; SR, sarcoma)
by CD14+ immunomagnetic beads and cultured under different methods as
labeled in X axis. Method A, fast-DC (28); B, ex vivo media with 5 days
culture as described (29, 30); C, 5 days culture in StemLine media and
GM-CSF, maturation factors TNFα and PGE2 added in the last 2 days of
culture; D, method C with IL-4 added for 5 days of culture; E, method D with
poly I:C added to maturation factors; F, method D with CpG used as
maturation factor in place of TNF-α (*p<0.05). (C) Decreased generation of
mDC correlates with increased percentage of CD14+HLA-DRlo/neg in the
monocytes selected for culture (Method B).
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Table 1 | Methods of CD14+HLA-DRlo/neg immune suppression.
CD14+HLA-DRlo/neg
functions
Targeted effect Reference
Altered STAT signals Resistance to
cytokine/TLR signaling
(16, 24)
Increased IDO expression Inhibits T-cell function (31–33)
Increased arginase
expression
Inhibits T-cell function (12, 24, 34)
Prevention of DC
maturation
Promotes immune
tolerance
(16–18)
Altered co-stimulatory
expression
Reduces T-cell stimulation (12, 14, 15, 35)
Altered cytokine
expression
Reduces T-cell stimulation (15, 35)
Decreased antigen uptake Reduces antigen-specific
T-cell responses
(35)
Increased iNOS and NOX2
production
Reduces T-cell stimulation (36)
Increased VEGF Inhibits DC differentiation (37)
Depletion of cytosine Inhibit T-cell activation (38, 39)
chambers of normal donors using immunomagnetic selection
(41). Control DCs were cultured with 1% human AB serum, stim-
ulated with GM-CSF and IL-4 (base media) for 3 days when one-
third volume of fresh base media was added. Non-adherent cells
were collected on day 6, re-suspended in base media with the addi-
tion of tumor necrosis factor alpha (TNF-α) and prostaglandin E2
(PGE2) to mature the DCs. This recipe is based on a classic method
of generation of mDCs (28, 29, 41). Alternatively, the system was
modified using a serum-free media and changes in cytokines to
generate mDCs (Figure 1B).
Cancer patients showed significant deficits in the ability to gen-
erate mDCs independent of the underlying tumor. There is also
substantially more variability in the efficiency of DC generation
using monocytes from cancer patients (Figure 1B). While we pri-
marily used CD83 up-regulation as indicative of DC maturation,
we also noted a lack of CD80 expression and specific functional
deficient of these cells. Increased efficiency of DC maturation can
be correlated with decreased presence of CD14+HLA-DRlo/neg
monocytes in the starting culture (Figure 1C). However, we could
consistently improve the ability to generate mDCs using serum-
free methods with the addition of IL-4. Even so, it was difficult to
recapitulate the efficient generation of mDCs we observed using
monocytes from healthy volunteers compared to cancer patients.
Knowing that CD14+HLA-DRlo/neg monocytes have significant
capacity to influence ex vivo DC cultures implies that these cells
and the pathways to both generate and eliminate them are high-
value targets to improve cancer therapies. It is striking to note that
these effects occurred in the complete absence of tumors and in
the continual presence (for days) with the cells in excess cytokines.
This deficit likely represents a significant block in the differen-
tiation pathway. This strongly suggests that immune stimulation
in vivo, even with precise targeting of the pathways known to
convert mature DC, is unlikely to efficiently trigger mDC matu-
ration in patients. Further understanding of the biology of these
CD14+HLA-DRlo/neg monocytes is needed; strategies to overcome
the effects of these cells can lead to better DC generation and
immune reconstitution.
IMPLICATIONS OF CD14+HLA-DRlo/neg ON DC-BASED
CANCER VACCINES
Most currently active DC-based cancer immunotherapy protocols
differ in either the cell source or some of the methods associ-
ated with the generation of DC. The most common approach has
been the ex vivo generation of mature DCs from patient myeloid-
derived monocyte precursors by co-culturing with GM-CSF and
various cocktails of cytokines and TLR agonists to produce mature
DCs. Optimizing DC culture conditions using normal healthy
donors will likely not directly translate into the protocols needed
for cancer patients. It will be important for those protocols that use
CD14+ cells to generate their DC product from primary patient
samples to confirm and optimize the manufacturing method and
assure that potent DCs are being generated. In our hands, a serum-
free method that includes IL-4 is a good starting point. Adequate
sampling size of the patient population is needed to determine the
range of differentiation efficiency in each specific cancer patient
population to inform the design of release criteria for vaccine
manufacturing. Our data also have clear implications for other
approaches attempting to mediate anti-tumor immune stimula-
tion. Adjuvants known to work in healthy people may not work
in cancer patients if their approach is to target the DC or DC
differentiation pathways.
As we improve our understanding of the importance of
CD14+HLA-DRlo/neg monocytes in promoting immunosuppres-
sion, it is imperative that we adjust our clinical practices to ensure
effective outcomes for patients using DC-based immunotherapy.
This will require continued efforts to develop optimal protocols
for generating ex vivo DC vaccine preparations and testing these
protocols in individual patients. The complexity of the human
immune system and individual tumor micro environments will
likely require an element of individualized protocol development
to achieve optimal clinical benefit.
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